Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen

Vaccine was shown to induce immunity against Prostate Stem Cell Antigen (PSCA) previously Full protein targeting expands the Self-Assembling Vaccine (SAV) platform’s potential targets NEW YORK, Nov. 20, 2023 /PRNewswire/ — Voltron Therapeutics, Inc., a Lucius Partners portfolio company,…